Can three-times-a-day cyclosporine neoral avoid cylosporine toxicity in renal transplant recipients? A pharmacokinetic study

Transplantation Proceedings

Volumn 33, Issue 7-8, 2001, Pages 3140-3141

  Swart, N ^a   Botha, J ^a   Tandon, V ^a   Michaels, P ^a   Pontin, A R ^a   Halkett, J ^a   Pascoe, M D ^a   Kahn, D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AZATHIOPRINE; BILIRUBIN; CYCLOSPORIN A; PREDNISONE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; SYSTOLIC BLOOD PRESSURE;

CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TIME FACTORS;

EID: 0035675666     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(01)02338-7     Document Type: Article

References (0)